AAV
Optimise AAV production with dbDNA™
dbDNA™ replaces traditional plasmid DNA in AAV manufacturing, requiring less DNA input material while eliminating unwanted bacterial sequences. The result is a higher-purity, more efficient process, designed to support consistent, scalable production of AAV-based therapies.
OVERVIEW
We’re accelerating AAV development with high-purity, scalable DNA solutions
40
less DNA per transfection
2
fold increase in full capsid percentage
1
AAV candidate in clinic
Benefits of AAV in your workflow
Touchlight’s enzymatic DNA technology eliminates common production challenges and pitfalls. Optimising your workflows using dbDNA provides you with superior yields and purity.
Higher titres using reduced amounts of input DNA.
Eliminates bacterial sequences for enhanced purity.
Supports complex or challenging sequences
Rapid GMP material production
Scalable manufacturing for clinical applications
Optimised vector performance for gene therapies
Touchlight vs competitors
Our approach eliminates the reliance on fermentation-based DNA production, improving the efficiency, purity, and scalability of your projects, compared to conventional methods.
RESOURCES
Learn more about dbDNA™ and its role in AAV development
Explore our latest research and insights into enzymatic DNA development innovations and how it enhances AAV production for next-generation therapies.
